A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: The study of pharmacotherapy of psychotic depression (STOP-PD)

Archives of General Psychiatry

Volumn 66, Issue 8, 2009, Pages 838-847

  Meyers, Barnett S ^a   Flint, Alastair J ^b,c   Rothschild, Anthony J ^d   Mulsant, Benoit H ^b,e,f   Whyte, Ellen M ^f   Peasley Miklus, Catherine ^a   Papademetriou, Eros ^a   Leon, Andrew C ^a   Heo, Moonseong ^a,g   Alexopoulos, G S ^h   Bruce, M L ^h   Klimstra, S ^h   English, J ^h   Gabriele, M ^h   Santana, F ^h   Addonizio, G ^h   De Asis, J ^h   Baran, X Y ^h   Kalyam, B ^h   Kupfer, D J ⁱ   Thase, M E ⁱ   Cohen, D J ⁱ   Emanuel, J E ⁱ   Kamara, T S ⁱ   Kephart, B ⁱ   Mathis, E R ⁱ   McLaughlin, N M ⁱ   McShea, M ⁱ   Gildengers, A G ⁱ   Howland, R H ⁱ   Miller, M D ⁱ   Rosen, J ⁱ   Appelbaum, P ^d   Candilis, P J ^d   Guerin, D ^d   Wood, C ^d   Rohrbaugh, A ^d   Fratoni, S ^d   Calkins, C ^d   Grogan, J ^d   Martin, M ^d   Patel, J ^d   Smith, E ^d   Reni, R ^d   Sit, D ^d   Kayatekin, E ^d   Morin, D ^d   Cimpeanu, C ^d   Shteinlukht, T ^d   Vemuri, M ^d   Bell, M ^d   Burke, P ^d   Byatt, N ^d   Cook, R ^d   Deligiannidis, K ^d   Guryanova, I ^d   Jastiniah, A ^d   Mathur, A ^d   Kasapinovic, S ^b   Andrade, C ^b   Zuker, P ^b   Rizvi, S ^b   Schaffer, A ^b   Herrmann, N ^b   Brook, S ^b   Silveira, J ^b   Olin, J ^j,k   Zachariah, E ^j   Evans, J ^j   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO REHABILITATION INSTITUTE   (Canada)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h WEILL CORNELL MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^k University of Toronto Affiliated Hospitals ^*  (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; SERTRALINE;

ADULT; AGED; ARTICLE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSIVE PSYCHOSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; EXTRAPYRAMIDAL SYMPTOM; FALLING; FEMALE; FOOT EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; LASSITUDE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORTHOSTATIC DIZZINESS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 68149125187     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2009.79     Document Type: Article

References (78)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
2. Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry. 1991;48 (12): 1075-1081.
3. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry. 2002;159(11): 1855-1861.
4. Coryell W, Leon A, Winokur G, Endicott J, Keller M, Akiskal H, Solomon D. Importance of psychotic features to long-term course in major depressive disorder. Am J Psychiatry. 1996;153(4): 483-489.
5. Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Phenomenology and prognostic significance of delusions in major depressive disorder: a 10-year prospective follow-up study. J Clin Psychiatry. 2007;68(9): 1411-1417.
6. Post F. The Significance of Affective Symptoms in Old Age: A Follow-up Study of One Hundred Patients. New York, NY: Oxford University Press; 1962.
7. Meyers BS, Greenberg R. Late-life delusional depression. J Affect Disord. 1986;11(2): 133-137.
8. Rothschild AJ, Samson JA, Bond TC, Luciana MM, Schildkraut JJ, Schatzberg AF. Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression. Biol Psychiatry. 1993;34(6): 392-400.
9. Vythilingam M, Chen J, Bremner JD, Mazure CM, Maciejewski PK, Nelson JC. Psychotic depression and mortality. Am J Psychiatry. 2003;160(3): 574-576.
10. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(4)(suppl): 1-45.
11. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care [NICE Clinical Guideline 23]. London, England: National Institute for Health and Clinical Excellence; 2004.
12. Friedman C, De Mowbray MS, Hamilton V. Imipramine (Tofranil) in depressive states: a controlled trial with inpatients. J Ment Sci. 1961;107: 948-953.
13. Hordern A, Holt NF, Burt CG, Gordon WF. Amitriptyline in depressive states: phenomenology and prognostic considerations. Br J Psychiatry. 1963;109: 815-825.
14. Avery D, Lubrano A. Depression treated with imipramine and ECT: the DeCarolis study reconsidered. Am J Psychiatry. 1979;136(4B): 559-562.
15. Glassman AH, Roose SP. Delusional depression: a distinct clinical entity? Arch Gen Psychiatry. 1981;38(4): 424-427.
16. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil JF, Perel JM, Rossi AJ, Soloff PH. The pharmacological treatment of delusional depression. Am J Psychiatry. 1985;142(4): 430-436.
17. Kroessler D. Relative efficacy rates for therapies of delusional depression. Convuls Ther. 1985;1(3): 173-182.
18. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord. 1992;24(1): 17-24.
19. Rothschild AJ, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, Van Campen LE, Sanger TM, Tollefson GD. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol. 2004;24(4): 365-373.
20. Andreescu C, Mulsant BH, Rothschild AJ, Flint AJ, Meyers BS, Whyte E. Pharmacotherapy of major depression with psychotic features: what is the evidence? Psychiatr Ann. 2006;36(1): 31-38.
21. Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA. Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry. 2006;188: 410-415.
22. Rothschild AJ, Winer J, Flint AJ, Mulsant BH, Whyte EM, Heo M, Fratoni S, Gabriele M, Kasapinovic S, Meyers BS; Study of Pharmacotherapy of Psychotic Depression (STOP-PD) Collaborative Study Group. Missed diagnosis of psychotic depression at 4 academic medical centers. J Clin Psychiatry. 2008;69(8): 1293-1296.
23. Mulsant BH, Haskett RF, Prudic J, Thase ME, Malone KM, Mann JJ, Pettinati HM, Sackeim HA. Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry. 1997;154(4): 559-561.
24. Andreescu C, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Caswell M, Whyte EM, Meyers BS; STOP-PD Study Group. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007;68(2): 194-200.
25. Mulsant BH, Sweet RA, Rosen J, Pollock BG, Zubenko GS, Flynn T, Begley AE, Mazumdar S, Reynolds CF III. A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry. 2001;62(8): 597-604.
26. Meyers BS, Klimstra SA, Gabriele M, Hamilton M, Kakuma T, Tirumalasetti F, Alexopoulos GS. Continuation treatment of delusional depression in older adults. Am J Geriatr Psychiatry. 2001;9(4): 415-422.
27. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11): 1079-1088.
28. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmen-tation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1): 131-134.
29. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry. 1996;153(12): 1631-1633.
30. Flint AJ, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry. 1998;13(1): 23-28.
31. Petrides G, Fink M, Husain MM, Knapp RG, Rush AJ, Mueller M, Rummans TA, O’Connor KM, Rasmussen KG Jr, Bernstein HJ, Biggs M, Bailine SH, Kellner CH. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT. 2001;17(4): 244-253.
32. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSMIV-TR Axis I Disorders-Patient Edition (SCID-I/P). New York, NY: Biometrics Research Dept, New York State Psychiatric Institute; 2001.
33. Meyers BS, English J, Gabriele M, Peasley-Miklus C, Heo M, Flint AJ, Mulsant BH, Rothschild AJ; STOP-PD Study Group. A delusion assessment scale for psychotic major depression: reliability, validity, and utility. Biol Psychiatry. 2006;60(12): 1336-1342.
34. Spitzer R, Endicott J. Schedule for Affective Disorders and Schizophrenia. 3rd ed. New York, NY: Biometrics Research Dept, New York State Psychiatric Institute; 1979.
35. Nelson JC, Bowers MB Jr. Delusional unipolar depression: description and drug response. Arch Gen Psychiatry. 1978;35(11): 1321-1328.
36. Parker G, Hadzi-Pavlovic D, Hickie I, Mitchell P, Wilhelm K, Brodaty H, Boyce P, Eyers K, Pedic F. Psychotic depression: a review and clinical experience. Aust N Z J Psychiatry. 1991;25(2): 169-180.
37. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149(6): 733-745.
38. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 56-62.
39. Williams JB, Kobak KA, Bech P, Engelhardt N, Evans K, Lipsitz J, Olin J, Pearson J, Kalali A. The GRID-HAM-D standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol. 2008;23(3): 120-129.
40. Guy W. Clinical Global Impressions: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Dept of Health, Education, and Welfare; 1976: 217-222.
41. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24: 97-99.
42. Andreasen N. The Scale for the Assessment of Positive Symptoms (SADS). Iowa City, IA: Department of Psychiatry, University of Iowa; 1984.
43. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF III. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41(3): 237-248.
44. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3): 189-198.
45. Georgotas A, McCue RE, Hapworth W, Friedman E, Kim OM, Welkowitz J, Chang I, Cooper TB. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry. 1986;21(12): 1155-1166.
46. Reynolds CF III, Frank E, Kupfer DJ, Thase ME, Perel JM, Mazumdar S, Houck PR. Treatment outcome in recurrent major depression: a post hoc comparison of elderly ("young old") and midlife patients. Am J Psychiatry. 1996;153(10): 1288-1292.
47. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334: 1-100.
48. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212: 11-19.
49. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154: 672-676.
50. Guy W. Abnormal Involuntary Movement Scale (AIMS): ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Dept of Health, Education, and Welfare; 1976: 534-537.
51. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4): 486-487.
52. Hedeker D, Gibbons RD. A random-effects ordinal regression model for multilevel analysis. Biometrics. 1994;50(4): 933-944.
53. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4): 800-802.
54. Thase ME, Pritchett YI, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol. 2007;27(6): 672-676.
55. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12): 1209-1223.
56. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5): 425-433.
57. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25(3): 255-258.
58. Lipkovich I, Citrome L, Perlis R, Deberdt W, Houston JP, Ahl J, Hardy T. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26(3): 316-320.
59. Smith E, Rothschild AJ, Heo M, Peasley-Miklus C, Caswell M, Papademetriou E, Flint AJ, Mulsant BH,Meyers BS; STOP-PD Collaborative Study Group. Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. Int Clin Psychopharmacol. 2008;23(3): 130-137.
60. Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry. 1977;34(2): 197-204.
61. Charney DS, Nelson JC. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry. 1981;138(3): 328-333.
62. Kocsis JH, Croughan JL, Katz MM, Butler TP, Secunda S, Bowden CL, Davis JM. Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression. Am J Psychiatry. 1990;147(5): 621-624.
63. Spiker DG, Dealy RS, Hanin I, Weiss JC, Kupfer DJ. Treating delusional depressives with amitriptyline. J Clin Psychiatry. 1986;47(5): 243-246.
64. Bruijn JA, Moleman P, Mulder PGH, van den Broek WW. Treatment of moodcongruent psychotic depression with imipramine. J Affect Disord. 2001;66(2-3): 165-174.
65. Birkenhager TK, van den Broek WW, Mulder PG, Moleman P, Bruijn JA. Efficacy of imipramine in psychotic versus nonpsychotic depression. J Clin Psychopharmacol. 2008;28(2): 166-170.
66. Alexopoulos GS, Katz IR, Reynolds CF III, Carpenter D, Docherty JP, Ross RW. Pharmacotherapy of depression in older patients: a summary of the expert consensus guidelines. J Psychiatr Pract. 2001;7(6): 361-376.
67. Rothschild AJ, Phillips KA. Selective serotonin reuptake inhibitors and delusional depression. Am J Psychiatry. 1999;156(6): 977-978.
68. Simpson GM, El Sheshai A, Rady A, Kingsbury SJ, Fayek M. Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression. J Clin Psychiatry. 2003;64(8): 959-965.
69. Spiker DG, Kupfer DJ. Placebo response rates in psychotic and nonpsychotic depression. J Affect Disord. 1988;14(1): 21-23.
70. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-controlled clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62(12): 1305-1312.
71. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol Psychiatry. 2006;59(11): 1001-1005.
72. Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology. 1992;6(1): 39-63.
73. Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, Pettinati HM, Greenberg RM, Crowe RR, Cooper TB, Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285(10): 1299-1307.
74. Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2008;63(4): 424-434.
75. Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ, McElhiney MC, Coleman EA, Settembrino JM. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med. 1993;328(12): 839-846.
76. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim HA. Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry. 2004;55(3): 301-312.
77. Robinson DG, Spiker DG. Delusional depression: a one year follow-up. J Affect Disord. 1985;9(1): 79-83.
78. Flint AJ, Rifat SL. Two-year outcome of psychotic depression in late life. Am J Psychiatry. 1998;155(2): 178-183.